[Glucosylated proteins and perinatal growth]

Area of Science:

• Neonatal Medicine
• Clinical Chemistry
• Pediatric Endocrinology

Background:

• Glycosylated proteins, including hemoglobin A1c (HbA1c), are indicators of long-term glycemic control.
• Assessing neonatal metabolic status is crucial for understanding infant development and health outcomes.
• Limited data exists on the relationship between glycosylated markers and early growth in newborns of varying gestational ages.

Purpose of the Study:

• To investigate the correlation between HbA1c and glycosylated serum proteins and infant maturity.
• To examine the relationship between these markers and prenatal and early postnatal growth in newborns.
• To evaluate the utility of glycosylated proteins as indicators of early development in neonates.

Main Methods:

• Colorimetric assays were employed to measure HbA1c and glycosylated serum proteins.
• Measurements were taken in 30 and 29 newborn infants, respectively.
• Infants were assessed at two postnatal time points: 0-24 hours and 19-23 days.

Main Results:

• No significant relationship was identified between infant maturity and the concentration of HbA1c or glycosylated serum proteins.
• No correlation was found between prenatal and early postnatal growth and the levels of these glycosylated markers.
• The study did not establish a link between glycosylated haemoglobin/serum proteins and infant growth parameters.

Conclusions:

• Early postnatal levels of HbA1c and glycosylated serum proteins do not appear to be associated with infant maturity or growth.
• These findings suggest that glycosylated proteins may not be reliable early indicators of developmental status or growth in newborns.
• Further research is needed to explore other potential biomarkers for neonatal growth and metabolic assessment.